Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. - Wikidata - wikimedia - TriplyDB

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

http://www.wikidata.org/entity/Q36167647

about

Hepatocellular carcinoma and hepatitis B surface protein Immune-mediated Liver Injury in Hepatitis B Virus Infection HBV induced HCC: major risk factors from genetic to molecular level Hepatitis B: future curative strategies Time for Integrating Clinical, Lifestyle and Molecular Data to Predict Drug Responses.Thrombocytosis and hepatocellular carcinoma.Role of platelets in chronic liver disease and acute liver injury.Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase.Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.Platelet-related phenotypic patterns in hepatocellular carcinoma patients.High seroprevalence of human herpesvirus type 8 in patients with hepatocellular carcinoma.Novel functions of platelets in the liver.Dynamic protein interaction modules in human hepatocellular carcinoma progression Induction of apurinic endonuclease 1 overexpression by endoplasmic reticulum stress in hepatoma cells.Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis.RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B.Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis.Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?Chemopreventive strategies in hepatocellular carcinoma Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade.Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma.Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Platelets harness the immune response to drive liver cancer.NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.Experimental models of liver fibrosis Effector CD8 T cell trafficking within the liver The preoperative platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma?Role of hemostatic factors in hepatic injury and disease: animal models de-liver.Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.Chemoprevention and novel therapy for hepatocellular carcinoma associated with chronic hepatitis B virus infection.Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding.Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.The immune tolerant phase of chronic HBV infection: new perspectives on an old concept Hepatic effector CD8(+) T-cell dynamics.Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation.Chronic hepatitis B: role of anti-platelet therapy in inflammation control.Immune Response in Hepatitis B Virus Infection.

P2860

Q26766123-1DF0C015-BA61-42EE-B3CB-BF619A915FF9 Q26786772-CD28B840-1516-4D61-9D2B-AC81F1988526 Q26825274-7F7877C1-2470-4A1A-B2C9-EABA3F97C0C2 Q27011623-06474C2B-16A2-4A81-9101-F38AFAB081C4 Q31109183-D160E0F4-0049-41AF-BD76-7771324B2ABC Q33405280-DE08374E-929E-4199-96DF-1092FE6991B2 Q33409013-DC270C4B-CDC7-4867-9B5C-4441A63712B0 Q33410073-0A8D1CEF-BD70-4A25-979D-6564DC36BC80 Q33412956-DE75566A-D501-4C72-AE10-503B156C4E05 Q33416414-3E543AC6-077C-496E-9985-228872FE52B9 Q33416416-3D0EB0BE-13D2-4FC8-B23B-1CA17DB2B12E Q33416527-C0B3D450-FA50-47F7-B477-F4A0B4F95D6A Q33428110-D12898E1-3225-4DCE-BECD-EA71584F2950 Q33644419-8A1E4D81-9B35-4AC4-90B8-30A6ED575FB9 Q34072423-5284834D-FA0A-4FB7-A6B6-EEAAFD7D5BB1 Q34178834-B57EC471-E4B4-47FC-8E49-C4F60090C4D4 Q34354947-0197B977-129D-40B6-B267-7079E8C9A16E Q34851047-0CA6C289-A17B-48B7-A88B-B97C887935C6 Q34992761-31728B97-DF6F-4F3A-888C-663EC8D27463 Q35053561-FAA2A06A-F823-4618-A5F5-6637DC60787D Q35075107-185C4801-CB61-4FFD-AA7F-501C99E4CC2F Q35101365-552743D3-AB67-43EF-BBFA-3DD6F5F2F502 Q35536490-526AB06F-AA4F-46DD-B304-42F07AE62B12 Q36009148-2E5355AB-D866-4571-962C-87AA85EDC35B Q36043123-E72B0BC5-1907-4DA1-AF90-4DA54FD9C360 Q36167520-321F03E6-CBEE-46C9-85B0-059B7B277461 Q36439797-8475A250-2F8A-40F2-875E-D3F13B997063 Q36442525-49D89839-C993-462F-98AE-A7E442CC1A60 Q36625986-0AAF7FAC-2568-4F72-9D2E-69BC1A225CDC Q36915015-0F7E5E69-A0DB-4706-98C4-8BF2A5B33BC1 Q37387653-34463CE9-91F1-4829-9CE9-198662E64017 Q37408920-E3FEE7CD-6908-4E29-AB65-FB82EE3EFD74 Q37584585-539DC9F6-00F1-4EDA-ADF3-BA21C85E3018 Q37645070-40DC69BB-BCE2-470C-AF18-3EF91C64DD21 Q38056849-A27F1806-DAEE-4B9A-8D05-672E265503C9 Q38245181-DEA80C04-A95D-4974-AE5A-18CC82A8A177 Q38252987-48F0F57F-BDF4-4A53-BC00-2F81EA4A88F5 Q38258081-590BD533-CB4D-4626-BB74-A0F03D05EA18 Q38314202-820F8C3D-7DE0-48F3-8AFF-6242340C4EAC Q38541811-40647647-D0B5-4D94-BBEE-012A34AFAF55

P2860

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

http://www.wikidata.org/entity/Q36167647

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@ast

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@en

type

label

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@ast

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@en

prefLabel

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@ast

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@en

P1433

Q36167647-A5389DD6-6723-4875-BF7A-E9B6FE8A3282

P1476

Q36167647-46509AA2-305D-4B7A-A58F-2189D62E0262

P2093

Q36167647-233FFDBE-2590-422E-9D07-DE1A7CAC7924

Q36167647-256E160F-5FFC-4098-91A6-C558253DB3AE

Q36167647-4E45D335-B967-4056-9B10-AAC5C153F9AD

Q36167647-545AA128-32EC-4CDE-A503-61DA90A5A8CE

Q36167647-A1E6D7FF-1C4B-4596-B841-03F210E40600

P2860

Q36167647-0104BB07-A16E-4F54-B0F3-8493B95D15E8

Q36167647-0C6869A1-1A14-47B1-A748-2C71556EEFA4

Q36167647-28DE7742-267C-4B08-BECA-0B50CB7D4422

Q36167647-2C05268B-C4FF-4EA1-9F6E-4DC0B78D4A0D

Q36167647-2FF31092-B5AA-4D54-A6A8-963E47B88DC7

Q36167647-30E5F259-7085-4A7B-A4B8-E4495CA87970

Q36167647-39F86664-7A41-4EB3-B66B-C2ADE8EB5BB1

Q36167647-3B4015B2-6260-4611-A3DA-47814B54FC25

Q36167647-3F221AE2-BC91-4838-B805-10798B1C4524

Q36167647-49B1BC6A-9344-4765-8C2E-72C7BB7DB6E1

P304

Q36167647-959EB44C-719D-4935-B7CE-C42B235B4800

P31

Q36167647-19107F56-970F-44BE-8880-32287FE68A4C

P356

Q36167647-5A754921-A623-482D-A9FD-E012BE10B9BB

P407

Q36167647-3058944F-13A5-4C2D-80E3-2358D2085C54

P433

Q36167647-F16C7927-A2D9-4A40-8EB6-2E7AC30A788B

P478

Q36167647-AFD9D877-6452-4E73-93F1-F08684BA408E

P50

Q36167647-38FB0F08-9C08-418E-8814-841A01153328

Q36167647-735EFC5B-2DBC-4725-BD51-8FA0FDD1D787

Q36167647-8299443D-90B4-4B33-BE4F-4BBFA5F2A978

Q36167647-AD551E0A-5E16-4324-A612-82A88CD64BE4

Q36167647-C802B541-03D6-4A45-89A9-C0FE7ABFA2C6

Q36167647-D2D8C24A-A5A3-4997-93CF-C607201DF621

P577

Q36167647-978494A3-E16B-4814-ABCC-F0E7AE7036E6

P5875

Q36167647-2ACC2E6A-3054-41AE-BD8D-EF0789DBE812

P698

Q36167647-AF1B9EEF-10A6-4B09-A0C4-0DC31AE04CB5

P932

Q36167647-EB2C271A-30D6-4F6B-9DE2-529812ADBCF1

P356

PNAS.1209182109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antiplatelet therapy prevents ...... model of chronic hepatitis B.

@en

P2093

Amleto Fiocchi

http://www.w3.org/2001/XMLSchema#string

Francesca Mingozzi

http://www.w3.org/2001/XMLSchema#string

Marta Mainetti

http://www.w3.org/2001/XMLSchema#string

Roberto Aiolfi

http://www.w3.org/2001/XMLSchema#string

Zaverio M Ruggeri

http://www.w3.org/2001/XMLSchema#string

P2860

Serotonin promotes tumor growth in human hepatocellular cancer

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

Platelets mediate cytotoxic T lymphocyte-induced liver damage.

Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis

Do human platelets express COX-2?

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus

Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice

Hepatitis B virus infection--natural history and clinical consequences

Histological grading and staging of chronic hepatitis

P304

E2165-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1209182109

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Francis V. Chisari

Matteo Iannacone

Luca G. Guidotti

Antonio Esposito

Pietro Di Lucia

P577

2012-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228105273

http://www.w3.org/2001/XMLSchema#string

P698

22753481

http://www.w3.org/2001/XMLSchema#string

P932

3420192

http://www.w3.org/2001/XMLSchema#string